Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment

European Journal of Endocrinology

Volumn 164, Issue 6, 2011, Pages 885-889

  Matta, Maria ^a   Bongard, Vanina ^a   Grunenwald, Solange ^a   Maiza, Jean Christophe ^a   Bennet, Antoine ^a   Caron, Philippe ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICAL RECORD REVIEW; METABOLIC PARAMETERS; PATIENT CODING; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; AGED; BODY MASS; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DISEASE MARKER; HORMONE BLOOD LEVEL; HYPOPITUITARISM; MAJOR CLINICAL STUDY; METABOLIC REGULATION; METABOLIC SYNDROME X; RADIOTHERAPY; RETROSPECTIVE STUDY;

ACROMEGALY; ADULT; AGED; AGING; BLOOD GLUCOSE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS INDEX; FEMALE; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX RATIO; SOMATOSTATIN;

EID: 79957781347     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0098     Document Type: Article

References (18)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
2. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K & Melmed S. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
3. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
4. Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008 159 89-95. (doi:10.1530/EJE-08-0267)
5. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM & Grossman AB. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. Journal of Clinical Endocrinology and Metabolism 2001 86 1645-1652. (doi:10.1210/jc.86.4.1645)
6. Bates AS, Evans AJ, Jones P & Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical Endocrinology 1995 42 417-423. (doi:10.1111/j.1365-2265.1995.tb02651.x)
7. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B & Maiter D. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 1324-1330. (doi:10.1210/jc.2007-2104)
8. Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clinical Endocrinology 2009 71 166-170. (doi:10.1111/j.1365-2265.2009.03556.x)
9. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF & Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3187-3191. (doi:10.1210/jc.82.10.3187)
10. Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jockel KH, Mohlenkamp S, Erbel R, Saller B & Mann K. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. Journal of Clinical Endocrinology and Metabolism 2010 95 3648-3656. (doi:10.1210/jc.2009- 2570)
11. Clauson PG, Brismar K, Hall K, Linnarsson R & Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scandinavian Journal of Clinical and Laboratory Investigation 1998 58 353-360. (doi:10.1080/00365519850186544)
12. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S & Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 15 314-322. (doi:10.1002/(SICI)1520-7560(199909/10)15:5〈314::AID-DMRR56〉3.0. CO;2-E)
13. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R & Soler J. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clinical Endocrinology 2003 58 213-219. (doi:10.1046/j.1365- 2265.2003.01698.x)
14. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB & Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745. (doi:10.1016/S0140-6736(02)08655-5)
15. Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebaek NE, Hilsted J & Skakkebae NE. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. Journal of Clinical Endocrinology and Metabolism 1995 80 1407-1415. (doi:10.1210/jc.80.4.1407)
16. Ezzat VA, Duncan ER, Wheatcroft SB & Kearney MT. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism 2008 10 198-211. (doi:10.1111/j.1463-1326.2007.00709.x)
17. Leung KC, Doyle N, Ballesteros M, Waters MJ & Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. Journal of Clinical Endocrinology and Metabolism 2000 85 4712-4720. (doi:10.1210/jc.85.12.4712)
18. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A & De Marinis L. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 2015-2022. (doi:10.1210/jc.2008-1337)